Message #7 From:
TheMachine Date: September 18, 2008 01:35:48 AM
Treatment of glioblastoma multiforme (GBM)
LIXT might be a THE solution. This companys board of advisers has credibility. Let us hope they deliver a cure for those that have glioblastoma multiforme (GBM).
Founded as a
biomarker-diagnostics company in 2005, the company is developing new
chemotherapy drugs by targeting molecular abnormalities of human
cancers. Over the past year, based on the discovery of a new biomarker
for brain cancers by collaborators at the National Institute of
Neurological Disorders and Stroke (NINDS), National Institutes of
Health (NIH), the company is evaluating new drugs for the treatment of
glioblastoma multiforme (GBM), the most common and most aggressive type
of primary brain cancer in adults and, to a much lesser extent, in
children. NINDS (www.ninds.nih.gov) is a component of the National
Institutes of Health (NIH), and is the nation’s primary supporter of
biomedical research on the brain and nervous system.
Over the next year, as part of its collaboration with NINDS,
the company plans to complete studies of the effectiveness of lead
compounds from each of two different classes of drugs developed by
Lixte that are active individually and, more so in combination, against
GBM in the test tube. Initial studies showed that these compounds
affect the intended biomarker target and have anti-tumor activity in a
mouse model of cancer. The next steps are characterization of
anti-tumor activity of these compounds in animal models of human GBM.
Subsequently, the toxicity profiles, pharmacologic behavior, and
metabolism of both classes of agents will be determined in pre-clinical
toxicology studies.
Should the results of the foregoing tests and studies prove successful,
Lixte hopes to satisfy FDA requirements for approval of, at least, one
lead compound for evaluation in Phase I trials in early 2009. Lixte
will also evaluate the anti-cancer activity of its new compounds in
model systems of two life-threatening cancers of children,
neuroblastoma and medulloblastoma, and against several common cancers
of adults in addition to GBM.
